Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.20 |
---|---|
High | 15.20 |
Low | 15.20 |
Bid | 15.90 |
Offer | 16.20 |
Previous close | 13.60 |
Average volume | 96.57 |
---|---|
Shares outstanding | 145.60m |
Free float | 122.62m |
P/E (TTM) | -- |
Market cap | 2.39bn USD |
EPS (TTM) | -0.5796 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 07:03 GMT.
More ▼
Announcements
- Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
- Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
- Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
- Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
- Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
- Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
- Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
More ▼